Belite Bio, Inc (BLTE)
| Market Cap | 6.11B +189.9% |
| Revenue (ttm) | n/a |
| Net Income | -102.36M |
| EPS | -2.74 |
| Shares Out | 40.27M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 171,256 |
| Open | 156.75 |
| Previous Close | 157.01 |
| Day's Range | 151.15 - 158.24 |
| 52-Week Range | 62.18 - 200.00 |
| Beta | -1.22 |
| Analysts | Strong Buy |
| Price Target | 214.00 (+41.05%) |
| Earnings Date | Aug 12, 2026 |
About BLTE
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical dev... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for BLTE stock is "Strong Buy." The 12-month stock price target is $214.0, which is an increase of 41.05% from the latest price.
News
Belite Bio to Host Virtual Commercial Day on September 2, 2026
SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targetin...
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
SAN DIEGO, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targetin...
Belite Bio price target raised to $206 from $201 at Morgan Stanley
Morgan Stanley analyst Judah Frommer raised the firm’s price target on Belite Bio (BLTE) to $206 from $201 and keeps an Overweight rating on the shares.
Belite Bio announces FDA acceptance, priority review of tinlarebant NDA
Belite Bio (BLTE) announced that the FDA has accepted and granted Priority Review designation of the NDA for tinlarebant for the treatment of Stargardt Disease Type 1. The FDA has…
Belite Bio price target raised to $214 from $200 at H.C. Wainwright
H.C. Wainwright analyst Yi Chen raised the firm’s price target on Belite Bio (BLTE) to $214 from $200 and keeps a Buy rating on the shares after the FDA accepted…
Belite Bio reports Q2 EPS (54c), consensus (78c)
As of June 30, the company had $279.9M in cash and cash equivalents, compared with $352.9M on December 31, 2025. “We continue to make significant strides in advancing tinlarebant in…
Belite Bio price target raised to $220 from $215 at Mizuho
Mizuho analyst Graig Suvannavejh raised the firm’s price target on Belite Bio (BLTE) to $220 from $215 and keeps an Outperform rating on the shares. The firm updated the company’s…
Belite Bio price target raised to $270 from $266 at Cantor Fitzgerald
Cantor Fitzgerald analyst Steve Seedhouse raised the firm’s price target on Belite Bio (BLTE) to $270 from $266 and keeps an Overweight rating on the shares. Belite Bio’s tinlarebant NDA…
Belite Bio price target raised to $206 from $201 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Belite Bio (BLTE) to $206 from $201 and keeps an Overweight rating on the shares after the company’s Q2 update. Following the…
Belite Bio Slides: Company presentation
Belite Bio has posted slides in relation to its latest quarterly earnings report, which was published on August 14, 2026.
Belite Bio Earnings Call Transcript: Q2 2026
FDA accepted the NDA for tinlarebant with priority review, setting a PDUFA date of Feb 12, 2027. Q2 saw increased R&D and SG&A expenses, a net loss of $28.4M, and a strong cash position of $780M. Pediatric and geographic atrophy studies are advancing, with global regulatory filings planned.
Belite Bio Earnings release: Q2 2026
Belite Bio released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update
SAN DIEGO, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targetin...
Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1
SAN DIEGO, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targetin...
Belite Bio to Host Webcast on August 13, 2026, to Discuss Second Quarter 2026 Financial Results
SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targetin...
Belite Bio Transcript: H.C. Wainwright 6th Annual Ophthalmology Virtual Conference
Panelists discussed promising advances in therapies for inherited retinal disorders, highlighting tinlarebant's substantial effect in slowing Stargardt disease progression and MCO-010's vision restoration in advanced RP. Both therapies show broad applicability, manageable safety, and are expected to transform patient care and the IRD treatment landscape.
Belite Bio Slides: Study result presentation
Belite Bio has posted slides in relation to its latest quarterly earnings report, which was published on July 21, 2026.
Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1
Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in Stargardt disease type 1, having met the primary efficacy endpoint, reduction in lesion growth Presentation to includ...
Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference
SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targetin...
Belite Bio Transcript: Piper Sandler Virtual Ophthalmology Day
Tinlarebant, an oral RBP4 antagonist, shows promise for Stargardt disease and geographic atrophy, with strong efficacy, a favorable safety profile, and regulatory momentum including breakthrough designation and anticipated priority review. Mild, manageable side effects and robust trial data support global filings.
Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium
SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targetin...
Belite Bio completes rolling submission of NDA to U.S. FDA for tinlarebant
Belite Bio (BLTE) announced the completion of its rolling submission of a New Drug Application, NDA, to the U.S. Food and Drug Administration, FDA, for tinlarebant. “The completion of our…
Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1
SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targetin...
Belite Bio Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Tinlarebant, an oral RBP4 antagonist, demonstrated significant efficacy and safety in slowing Stargardt disease progression, with a strong regulatory and commercial strategy targeting a large U.S. patient population. Expansion into other IRDs is under consideration.
Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targetin...